| http://www.w3.org/ns/prov#value | - In his opening remarks, Kenneth C. Anderson, MD, Director of the Jerome Lipper Multiple Myeloma Center and the LeBow Institute for Myeloma Therapeutics and Kraft Family Professor of Medicine at Dana-Farber Cancer Institute, noted that all of the novel agents used to treat multiple myeloma, including bortezomib, lenalidomide, and more recently carfilmozib, and pomalidomide, were approved for use in
|
